Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 6/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 5/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131176 | 1.00 | ATM (0.47) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL21513491 | 0.87 | ATM (0.46) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL29969221 | 0.86 | ATM (0.47) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL29968635 | 0.85 | PRKDC (0.46) | ATMPRKDCPIK3CDACVR1 | |
| SCHEMBL21513819 | 0.85 | PRKDC (0.46) | ATMPRKDCPIK3CDACVR1 | |
| SCHEMBL21513255 | 0.84 | MTOR (0.49) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL29968579 | 0.84 | MTOR (0.49) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL29969038 | 0.84 | ATM (0.47) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL21851056 | 0.82 | ATM (0.46) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL21513256 | 0.81 | NPC1 (0.45) | ATMPIK3CAMTORPRKDCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ATM 1/4885PIK3CA 480/4885MTOR 660/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ATM 1/4885PIK3CA 480/4885MTOR 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.